NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Friday morning. The brokerage issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Down 1.8 %

Shares of NURO stock opened at $4.43 on Friday. The company has a market capitalization of $9.09 million, a price-to-earnings ratio of -0.97 and a beta of 2.15. The firm has a 50-day moving average price of $4.35 and a 200 day moving average price of $4.15. NeuroMetrix has a twelve month low of $2.66 and a twelve month high of $4.73.

Institutional Trading of NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned about 0.57% of NeuroMetrix as of its most recent SEC filing. 19.40% of the stock is owned by hedge funds and other institutional investors.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.